Biotie Therapies - Notice to general meeting

Invitation to The Annual General Meeting of Biotie Therapies Corp.

BIOTIE THERAPIES CORP.           STOCK EXCHANGE RELEASE       17 March 2010  at
12.00

INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.

Notice is given to the shareholders of Biotie Therapies Corp. to the Annual
General Meeting to be held on Thursday, 15 April 2010 at 10 a.m. in an
auditorium at the premises of restaurant Alabama, address Lemminkäisenkatu
14-18 B, Turku, Finland. The reception of shareholders who have registered for
the meeting and the distribution of voting tickets will commence at 9:30 a.m.

A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING

At the Annual General Meeting, the following matters will be considered:

1. Opening of the meeting

2. Calling the meeting to order

3. Election of persons to confirm the minutes and to supervise the counting of
votes

4. Recording the legality of the meeting

5. Recording the attendance at the meeting and adoption of the list of votes

6. Presentation of the financial statements, the report of the Board of
Directors and the auditor's report for the year 2009
- Review by the CEO
- The company's equity is less than a half of the share capital, if the capital
loans are not counted among the items of the company's shareholders' equity.
Possible measures to remedy the financial position of the company.

7. Adoption of the financial statements

8. Booking of the loss of the financial year
The Board of Directors proposes that loss of the financial year 2009 shall be
transferred to the unrestricted equity and no dividend shall be distributed.

9. Resolution on the discharge of the members of the Board of Directors and the
Managing Director from liability

10. Resolution on the remuneration of the members of the Board of Directors
The Board of Directors proposes on the basis of the recommendation of the
Nomination and Remuneration Committee that the remuneration payable to the
members of the Board of Directors would be as follows: EUR 4,000 per month for
the Chairman and EUR 3,000 per month for other Board members. In addition, it is
proposed that reasonable travelling expenses for the meetings would be
compensated.

11. Resolution on the number of members of the Board of Directors
The Board of Directors proposes on the basis of the recommendation of the
Nomination and Remuneration Committee that the number of members of the Board of
Directors would be eight (8).

12. Election of members of the Board of Directors
The Board of Directors proposes on the basis of the recommendation of the
Nomination and Remuneration Committee that Peter Fellner, Ann Hanham, Bernd
Kastler, Pauli Marttila, Riku Rautsola and Pierre Serrure would be re-elected as
members of the Board of Directors and Merja Karhapää, Chief Legal Officer of
Sanoma Corporation, and James S. Shannon, CEO of Cerimon Phamaceuticals, Inc.,
would be elected as new members of the Board of Directors for the term expiring
at the end of the following annual general meeting.  Ms. Karhapää and Dr.
Shannon have given their consent regarding the appointment.

The current board members Juha Jouhki and Christoph Schröder have informed that
they are not available for election.

Dr. James S. Shannon, 54, currently serves as CEO and a director of Cerimon
Pharmaceuticals, and a director of Mannkind Corporation and Endocyte Inc.
Previously he was with Novartis Pharma from 1995 to 2008 most recently as Global
Head, Pharma Development. Prior to this he was with Sterling research group from
1987 to 1994. Dr. Shannon holds a Doctor of Medicine degree from Queens
University, UK.

Ms. Merja Karhapää, 47, currently serves as Chief Legal Officer (CLO, Group
Legal Affairs) and Secretary of the Board of Directors of Sanoma Corporation
(Company Secretary). She has served Sanoma Corporation since 2000 as Vice
President, Group Legal Affairs. Previously Ms. Karhapää worked as Vice
President, Intellectual Capital of Danisco, Trademark Counsel and Assistant
General Counsel of Cultor and Danisco in 1996-2000 and as Corporate Counsel of
Sanoma (former Sanoma News) and that of Valmet. Ms Karhapää holds a LL.M. degree
from University of Helsinki and a Postgraduate IPR Diploma from University of
Bristol.

13. Resolution on the remuneration of the auditors
The Board of Directors proposes on the basis of the recommendation of the Audit
Committee that the auditors' fees would be paid pursuant to a reasonable
invoice.

14. Election of auditors
The Board of Directors proposes on the basis of the recommendation of the Audit
Committee that PricewaterhouseCoopers Oy, a firm of auditors approved by the
Central Chamber of Commerce, and Mr Janne Rajalahti, Authorised Public
Accountant, would be elected as the auditors of the company.

15. Authorizing the Board of Directors to decide on the issuance of shares as
well as the issuance of options and other rights entitling to shares

The Board of Directors proposes that the Annual General Meeting would authorise
the Board of Directors to resolve on one or more issues which contains the right
to issue new shares or dispose of the shares in the possession of the company
and to issue options or other rights to the shares pursuant to chapter 10 of the
Companies Act. The authorisation would consist of up to 80,000,000 shares in
aggregate.

The authorisation would not exclude the Board of Directors' right to decide on a
directed issue. The authorisation is proposed to be used for material
arrangements from the company's point of view, such as financing or implementing
business arrangements or investments or for other such purposes determined by
the Board of Directors in which case a weighty financial reason for issuing
shares, options or other rights and possibly directing a share issue would
exist.

The Board of Directors would be authorised to resolve on all other terms and
conditions of a share issue, options and other share entitlements as referred to
in chapter 10 of the Companies Act, including the payment period, determination
grounds for the subscription price and subscription price or allocation of
shares, option or other rights free of charge or that the subscription price may
be paid besides in cash also by other assets either partially or entirely.

The authorisation would be effective until 30 June 2011. The Board of Directors
proposes that the authorisation would supersede earlier authorisations.

16. Closing of the meeting

B. DOCUMENTS OF THE ANNUAL GENERAL MEETING

The proposals of the Board of Directors relating to the agenda of the Annual
General Meeting as well as this notice are available on Biotie Therapies Corp.'s
website at www.biotie.com. In addition, the annual report of Biotie Therapies
Corp., including the company's financial statements, the report of the Board of
Directors and the auditor's report, is available on the above-mentioned website.
The proposals of the Board of Directors and the financial statements are also
available at the meeting. Copies of these documents and of this notice will be
sent to shareholders upon request. The minutes of the meeting will be available
on the above-mentioned website as from 29 April 2010.

C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING

1. The right to participate and registration

Each shareholder, who is registered on 1 April 2010 in the shareholders'
register of the company held by Euroclear Finland Ltd, has the right to
participate in the Annual General Meeting. A shareholder, whose shares are
registered on his/her personal Finnish book-entry account, is registered in the
shareholders' register of the company.

A shareholder, who wants to participate in the Annual General Meeting, shall
register for the meeting no later than 12 April 2010 at 10:00 a.m. Finnish time
by giving a prior notice of participation. Such notice can be given:

a) by e-mail to virve.nurmi@biotie.com;
b) by telephone +358 2 274 8911; or
c) by regular mail to Biotie Therapies Corp. / Virve Nurmi, Tykistökatu 6,
FI-20520 Turku, Finland.

In connection with the registration, a shareholder shall notify his/her name,
personal identification number, address, telephone number and the name of a
possible assistant or proxy representative and the personal identification
number of a proxy representative. The personal data given to Biotie Therapies
Corp. is used only in connection with the Annual General Meeting and with the
processing of related registrations.

Pursuant to chapter 5, section 25 of the Companies Act, a shareholder who is
present at the Annual General Meeting has the right to request information with
respect to the matters to be considered at the meeting.

2. Proxy representative and powers of attorney

A shareholder may participate in the Annual General Meeting and exercise his/her
rights at the meeting by way of proxy representation.

A proxy representative shall produce a dated proxy document or otherwise in a
reliable manner demonstrate his/her right to represent the shareholder at the
Annual General Meeting. When a shareholder participates in the Annual General
Meeting by means of several proxy representatives representing the shareholder
with shares at different securities accounts, the shares by which each proxy
representative represents the shareholder shall be identified in connection with
the registration for the Annual General Meeting.

Possible proxy documents should be delivered in original to the company before
the last date for registration.

3. Holders of nominee registered shares

A holder of nominee registered shares is advised to request without delay from
his/her custodian bank necessary instructions regarding the registration in the
shareholders' register of the Company, the issuing of proxy documents and
registration for the Annual General Meeting. The account management organization
of the custodian bank will register the holder of nominee registered shares, who
wants to participate in the Annual General Meeting, to be temporarily entered
into the shareholders' register of the company at the latest on 12 April 2010 at
10 a.m. Finnish time.

4. Other information

On the date of this notice to the Annual General Meeting, 17 March 2010, the
total number of shares and votes in Biotie Therapies Corp. is 158,752,560. Of
these shares, 463,255 are owned by Biotie Therapies Corp.

In Turku, 17 March 2010

Biotie Therapies Corp.
Board of Directors

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com


 DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media


[HUG#1394818]